Pressure BioSciences (OTCQB: PBIO) announced Friday that two separate research groups presented data at a recent scientific world congress showing that the inclusion of the company's pressure cycling technology (PCT) platform into their sample preparation processes resulted in a "marked improvement in the quality and/or efficiency of test results."
The studies were presented by scientists from the Center for Biologics Evaluation and Research of the Food and Drug Administration and from Janssen Research and Development at the HUPO 11th annual world congress in Boston.
Pressure BioSciences' PCT platform uses rapid and repeating cycles of hydrostatic pressure at controlled temperatures to extract cell components in the preparation of a biological sample, such as DNA and proteins from humans, animals and plants, for further study.
Its PCT products can be used for mass spectrometry, biomarker discovery, bio-therapeutics, vaccine development, forensics, and counter-bioterror applications, among other applications.
The first study, presented by scientists from the FDA, reported that PCT was an important part of their approach to improve sample preparation and protein identification. The authors of the study said the approach allowed them to better identify and analyze events likely to control the biology of multipotent stromal cells - which offer potential for cell-based therapies for a wide number of diseases.
Meanwhile, scientists from the Janssen team reported that PCT was "very effective in significantly reducing" the total time required to digest monoclonal proteins and to expedite their complete characterization. Monoclonal antibodies are used in diagnostics and therapeutics, and it is necessary to characterize them before use, which requires a digestion process that can be time consuming,Pressure BioSciences said.
"We are very pleased that two highly respected scientific teams have shown that the incorporation of the PCT Platform in their sample preparation workflow resulted in significant advantages, including savings in analysis time and improvements in test and result quality," said VP of sales and marketing, Dr. Nate Lawrence.
"Cell-based therapies are believed to offer enormous potential for improving human healthcare and the quality of life. The monoclonal antibody market is believed to be in the tens of billions of dollars.
"Consequently, we believe that the results presented by FDA and Janssen scientists at HUPO 2012 bode well for an increased demand of our PCT Platform in 2013 and beyond."
Earlier this week, Pressure BioSciences said a keynote speech, to be delivered by microbiologist and infectious diseases expert Dr. Bradford Powell at the Clinical Microbiology & Microbial Genomics Conference, could help to increase visibility of its PCT platform.
Powell is scheduled to present the keynote address during the opening ceremony of ClinMicro-2012 in San Antonio, Texas from November 12 to 14.
In the keynote address and a second, main session presentation later in the conference, the company said Powell is expected to present data highlighting the advantages of its PCT platform that has been shown to enable "significant improvements" in molecular-based microbiological testing - a "rapidly growing and extremely important" area in laboratory medicine today.
In August, the company said revenues from the sale of PCT products and services was $224,384 for the second quarter, up 18 per cent from a year ago.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.